Share This Author
Pharmacokinetic drug-drug interaction and their implication in clinical management
- C. Palleria, A. Di Paolo, L. Gallelli
- Medicine, BiologyJournal of research in medical sciences : the…
- 1 July 2013
In this review, using Medline, PubMed, Embase, Cochrane library and Reference lists, articles published until June 30 2012 are searched, and the mechanism of pharmacokinetic DDIs are described focusing the interest on their clinical implications.
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
This biweekly chemotherapy regimen with oxaliplatin, L-OHP, irinotecan, infusional fluorouracil, and leucovorin in metastatic colorectal cancer patients is feasible and has acceptable and manageable toxicities and no apparent relevant pharmacokinetics interactions.
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
- R. Danesi, F. Innocenti, M. del Tacca
- Medicine, ChemistryBritish journal of clinical pharmacology
- 1 May 2002
The slope factor of the Emax relationship between neutropenia and tC0.1 of paclitaxel suggests that the drugs might also interact at the pharmacodynamic level, and Cremophor EL markedly inhibited the metabolism of epirubicin to epirUBicinol in whole blood.
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma.
Overall results indicate that it is feasible to analyze all the anthracyclines used in clinical practice and their major metabolites with a single optimized method, thereby simplifying their monitoring in chemotherapeutic regimens of cancer patients.
A pharmacokinetic‐based test to prevent severe 5‐fluorouracil toxicity
5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer
Pharmacokinetics of 5-FU should be regarded as an important factor for predicting disease recurrence in colorectal cancer patients given adjuvant chemotherapy within a nonrandomized, retrospective, pharmacokinetic study.
Augmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study
- A. Benedetti, A. Di Paolo, G. Cassano
- Psychology, MedicineClinical practice and epidemiology in mental…
- 4 June 2010
The augmentation of clozapine with aripirazole was safe and effective in severe psychotic schizoaffective and bipolar disorders which failed to respond to atypical antipsychotics.
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
- A. Di Paolo, R. Danesi, M. del Tacca
- Medicine, BiologyAnnals of oncology : official journal of the…
- 1 September 2001
DPD activity in PBMNC is unrelated to 5-FU/5-FDHU disposition and patients with severe toxicity display marked pharmacokinetic alterations while a reduction of DPD activity may not occur.
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
- G. Bocci, R. Danesi, M. del Tacca
- Biology, MedicineClinical cancer research : an official journal of…
- 1 August 2000
The results of the present study provide the first detailed comparison of the distribution of 5-FU and its major metabolite 5-FDHU at the therapeutic level as well as at reduced test dose levels to obtain pharmacokinetic data to be used as reference values for the identification of patients at risk of major5-FU toxicity due to impaired metabolism to 5- FDHU.
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
In vivo, the CPT-11 metronomic schedule is effective against tumour and microvessel growth without toxic effect on mice, and in vitro results show the antiangiogenic properties of low-concentration SN-38, suggesting a key role of TSP-1 in this effect.